|
[1]LOK AS, ZOULIM F, DUSHEIKO G, et al.Hepatitis B cure:From discovery to regulatory approval[J].J Hepatol, 2017, 67 (4) :847-861.
|
|
[2]YANG HC, CHEN PJ.The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA[J].Virus Res, 2018, 244:304-310.
|
|
[3]European Association for the Study of the Liver.EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J].J Hepatol, 2017, 67 (2) :370-398.
|
|
[4]KESHVARI M, SALI S, SHARAFI H, et al.P0594:Can serum level of hepatitis B surface antigen (HBsAg) differentiate HBsAg inactive carrier state from chronic hepatitis B?[J].J Hepatol, 2015, 62:s539.
|
|
[5]HONER ZU SIEDERDISSEN C, MAASOUMY B, CORNBERG M.What is new on HBsAg and other diagnostic markers in HBV infection?[J].Best Pract Res Clin Gastroenterol, 2017, 31 (3) :281-289.
|
|
[6]ZEISEL MB, LUCIFORA J, MASON WS, et al.Towards an HBVcure:state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure[J].Gut, 2015, 64 (8) :1314-1326.
|
|
[7]URBAN S, SCHULZE A, DANDRI M, et al.The replication cycle of hepatitis B virus[J].J Hepatol, 2010, 52 (2) :282-284.
|
|
[8]SUN S, NAKASHIMA K, ITO M, et al.Involvement of PUF60 in transcriptional and post-transcriptional regulation of hepatitis B virus pregenomic RNA expression[J].Sci Rep, 2017, 7 (1) :12874.
|
|
[9]WANG JC, DHASON MS, ZLOTNICK A.Structural organization of pregenomic RNA and the carboxy-terminal domain of the capsid protein of hepatitis B virus[J].PLo S Pathog, 2012, 8 (9) :e1002919.
|
|
[10]RYU DK, AHN Y, RYU WS, et al.Development of a novel hepatitis B virus encapsidation detection assay by viral nucleocapsidcaptured quantitative RT-PCR[J].Biotechniques, 2015, 59 (5) :287-293.
|
|
[11]WANG J, SHEN T, HUANG X, et al.Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J].J Hepatol, 2016, 65 (4) :700-710.
|
|
[12]VAN BOMMEL F, BARTENS A, MYSICKOVA A, et al.Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J].Hepatology, 2015, 61 (1) :66-76.
|
|
[13]HALGAND B, DESTERKE C, RIVIERE L, et al.Hepatitis B virus pregenomic RNA in hepatocellular carcinoma:A nosological and prognostic determinant[J].Hepatology, 2018, 67 (1) :86-96.
|
|
[14]NASSAL M.HBV ccc DNA:Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J].Gut, 2015, 64 (12) :1972-1984.
|
|
[15]JUNG KS, PARK JY, CHON YE, et al.Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients[J].J Gastroenterol, 2016, 51 (8) :830-839.
|
|
[16]MATSUZAKI T, TATSUKI I, OTANI M, et al.Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation[J].J Gastroenterol Hepatol, 2013, 28 (7) :1217-1222.
|
|
[17]LU FM, WANG J, CHEN XM, et al.The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B[J].Chin J Hepatol, 2017, 25 (2) :105-110. (in Chinese) 鲁凤民, 王杰, 陈香梅, 等.乙型肝炎病毒RNA病毒样颗粒的发现及其对抗病毒治疗临床实践的潜在影响[J].中华肝脏病杂志, 2017, 25 (2) :105-110.
|
|
[18]BAI F, YANO Y, FUKUMOTO T, et al.Quantification of pregenomic RNA and covalently closed circular DNA in hepatitis B virus-related hepatocellular carcinoma[J].Int J Hepatol, 2013, 2013:849290.
|
|
[19]HATAKEYAMA T, NOGUCHI C, HIRAGA N, et al.Serum HBVRNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine[J].Hepatology, 2007, 45 (5) :1179-1186.
|
|
[20]HUANG H, WANG J, LI W, et al.Serum HBV DNA plus RNAshows superiority in reflecting the activity of intrahepatic ccc DNA in treatment-naive HBV-infected individuals[J].J Clin Virol, 2018, 99-100:71-78.
|
|
[21]SETO WK, WONG DK, CHAN TS, et al.Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy[J].Am J Gastroenterol, 2016, 111 (12) :1788-1795.
|
|
[22]MAASOUMY B, WIEGAND SB, JAROSZEWICZ J, et al.Hepatitis Bcore-related antigen (HBcr Ag) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D[J].Clin Microbiol Infect, 2015, 21 (6) :606e1-10.
|
|
[23]SETO WK, TANAKA Y, WONG DK, et al.Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay[J].Hepatol Int, 2012, 7 (1) :98-105.
|
|
[24]LUCKENBAUGH L, KITRINOS KM, DELANEY WET, et al.Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy[J].J Viral Hepat, 2015, 22 (6) :561-570.
|
|
[25]CHEN EQ, FENG S, WANG ML, et al.Serum hepatitis B corerelated antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B[J].Sci Rep, 2017, 7 (1) :173.
|
|
[26]HONDA M, SHIRASAKI T, TERASHIMA T, et al.Hepatitis B virus (HBV) core-related antigen during nucleos (t) ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma[J].J Infect Dis, 2016, 213 (7) :1096-1106.
|
|
[27]LIU RX, PAN XC, GENG J.Clinical value of serum HBV RNA[J].J Clin Hepatol, 2017, 33 (11) :2196-2199. (in Chinese) 刘瑞霞, 潘修成, 耿建.血清HBV RNA检测的临床价值[J].临床肝胆病杂志, 2017, 33 (11) :2196-2199.
|
|
[28]TU T, BUDZINSKA MA, VONDRAN FWR, et al.Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via NTCP-dependent uptake of enveloped virus particles[J].J Virol, 2018, 92 (12) :e02007-e02017.
|
|
[29] ARZUMANYAN A, REIS HM, FEITELSON MA.Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma[J].Nat Rev Cancer, 2013, 13 (2) :123-135.
|
DownLoad: